Syapse said Thursday it will bring its “precision medicine” software, which aims to tailor treatments to the underlying genetics of diseases, to cancer-treatment centers run by the Hospital Corp. of America, one of the world’s largest for-profit health care providers.
The software will be used with 100,000 cancer patients at more than 75 centers operated by Sarah Cannon, the Hospital Corporation of America’s cancer-treatment arm, in the United Kingdom and the United States.
Not all cancers are alike, and a new trend in medicine called “precision medicine,” highlighted in President Obama’s State of the Union this month, calls for using knowledge gained from sequencing the human genome to create better, more effective therapies for ailments of all kinds.
Syapse’s software will allow providers to dig into the genomic characteristics of cancer tumors, analyze them, integrate them with medical records, and use those insights to develop personalized plans for diagnosing, treating and tracking patients’ health. In addition, the software will match the latest clinical trials for cancer drugs to patients whose profiles indicate they may respond well to the therapies.
Financial terms of the deal were not disclosed. Syapse has raised more than $14 million in venture funding, according to CrunchBase. Its other customers include UCSF, Stanford University School of Medicine, Intermountain Healthcare and the Roswell Park Cancer Institute.
“Combining clinical history, treatments, genomics, outcomes and other relevant data within one system will help our physicians and researchers more rapidly identify patterns in patient data that support the development of personalized treatment plans for patients,” said Dr. Howard A. “Skip” Burris III, president of clinical operations for Sarah Cannon, in a statement.
